{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:03:55Z","timestamp":1782846235157,"version":"3.54.5"},"reference-count":47,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Cancer"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, but their safety profile in patients with thymic epithelial tumors (TETs) remains poorly characterized due to the rarity of these malignancies.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n This study aims to comprehensively analyze immune-related adverse events (irAEs) profiles in patients with TETs using real-world pharmacovigilance data.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We conducted a retrospective analysis of the US Food and Drug Administration Adverse Event Reporting System database from the first quarter of 2016 through the fourth quarter of 2024. Cases of TETs with ICI-related adverse events were identified and deduplicated following Food and Drug Administration recommendations. Disproportionality analysis was performed by calculating odds ratios, using the entire US Food and Drug Administration Adverse Event Reporting System database as the reference cohort. Signals were defined as significant with at least 3 cases and a lower 95% CI exceeded 1. Time-to-onset analysis and Weibull Shape Parameter testing were used to characterize the temporal pattern of irAEs. Clinical characteristics between fatal and nonfatal cases and cardiotoxicity specifics were analyzed descriptively.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among 152 eligible TET cases with irAEs, males slightly predominated (80\/152, 52.6%), with a median age of 58.5 years. Reports originated predominantly from the United States (51\/152, 33.6%) and Japan (16\/152, 10.5%). PD-1 inhibitors were implicated in 66.4% (101\/152) of cases. Disproportionality analysis identified 14 significant irAE signals across 11 System Organ Classes. Myositis (reporting odds ratio [ROR] 113.15, 95% CI 26.65\u2010480.34), myocarditis (ROR 10.96, 95% CI 5.70\u201021.07), myasthenia gravis (ROR 3.86, 95% CI 1.86\u20107.85), and febrile neutropenia (ROR 18.33, 95% CI 4.57\u201073.55) demonstrated the strongest associations. The median time to irAEs onset was 21.0 days, with 73.2% (41\/56) occurring within 2 months of treatment initiation. Fatal outcomes were reported in 23.7% (36\/152) of cases and were significantly associated with gender distribution (\n P<\/jats:italic>\n =.04) and different treatment strategies (\n P<\/jats:italic>\n =.01). The utilization of PD-1 inhibitors was higher in the fatal group (29\/36, 80.06%) than in the nonfatal group (72\/116, 62.1%). Myocarditis was the most frequent cardiotoxicity, accounting for 51.3% (20\/39) of cardiac events.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n This large-scale pharmacovigilance study delineates a distinct and severe irAEs profile for ICIs in patients with TETs, characterized by robust disproportionality signals for myositis, cardiotoxicity, and myasthenia gravis. As a hypothesis-generating analysis, these findings underscore the need for vigilant monitoring and early detection strategies to mitigate irAE risks, particularly in high-risk subgroups such as patients with thymoma. The results provide clinically relevant evidence to guide risk-benefit evaluation and inform tailored surveillance protocols during ICI therapy in this population.<\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/76908","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T18:50:06Z","timestamp":1767379806000},"page":"e76908-e76908","source":"Crossref","is-referenced-by-count":0,"title":["Immunotherapy Safety in Thymic Epithelial Tumors: Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System"],"prefix":"10.2196","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3718-3843","authenticated-orcid":false,"given":"Ruilian","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0058-6609","authenticated-orcid":false,"given":"Hanrui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0991-672X","authenticated-orcid":false,"given":"Lingling","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3230-5346","authenticated-orcid":false,"given":"Yang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0436-4394","authenticated-orcid":false,"given":"Lizhu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"issue":"2","key":"R1","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jtho.2021.10.010","article-title":"The 2021 WHO classification of tumors of the thymus and mediastinum: what is new in thymic epithelial, germ cell, and mesenchymal tumors?","volume":"17","author":"Marx","journal-title":"J Thorac Oncol"},{"issue":"4","key":"R2","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s12094-022-02788-w","article-title":"SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021)","volume":"24","author":"Remon","journal-title":"Clin Transl Oncol"},{"issue":"4","key":"R3","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3760\/cma.j.cn112152-20210313-00226","article-title":"Chinese guideline for clinical diagnosis and treatment of thymic epithelial tumors (2021 Edition)","volume":"43","author":"Multidisciplinary Committee of Oncology, Chinese Physicians Association","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102014","article-title":"Thymic epithelial tumors: from biology to treatment","volume":"86","author":"Conforti","journal-title":"Cancer Treat Rev"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv277","article-title":"Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Girard","journal-title":"Ann Oncol"},{"issue":"4","key":"R6","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"R7","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.cell.2018.09.035","article-title":"A paradigm shift in cancer immunotherapy: from enhancement to normalization","volume":"175","author":"Sanmamed","journal-title":"Cell"},{"issue":"12","key":"R8","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","article-title":"Predictive biomarkers for checkpoint inhibitor-based immunotherapy","volume":"17","author":"Gibney","journal-title":"Lancet Oncol"},{"issue":"8","key":"R9","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","journal-title":"Cell Mol Immunol"},{"issue":"12","key":"R10","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/1759-7714.14847","article-title":"Chinese expert consensus on the diagnosis and treatment of thymic epithelial tumors","volume":"14","author":"Xu","journal-title":"Thorac Cancer"},{"issue":"3","key":"R11","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.jtho.2020.11.003","article-title":"Durable response in patients with thymic carcinoma treated with pembrolizumab after prolonged follow-up","volume":"16","author":"Giaccone","journal-title":"J Thorac Oncol"},{"issue":"3","key":"R12","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","journal-title":"Lancet Oncol"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.03.012","article-title":"Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study","volume":"113","author":"Katsuya","journal-title":"Eur J Cancer"},{"issue":"1","key":"R14","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0723-9","article-title":"Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma","volume":"7","author":"Rajan","journal-title":"J Immunother Cancer"},{"issue":"2","key":"R15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.thorsurg.2018.12.001","article-title":"The role of the thymus in the immune response","volume":"29","author":"Thapa","journal-title":"Thorac Surg Clin"},{"issue":"1","key":"R16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41416-024-02887-1","article-title":"Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review","volume":"132","author":"Jayathilaka","journal-title":"Br J Cancer"},{"issue":"3","key":"R17","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101576","article-title":"Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial","volume":"8","author":"Girard","journal-title":"ESMO Open"},{"issue":"5","key":"R18","doi-asserted-by":"publisher","first-page":"5649","DOI":"10.1002\/cam4.5357","article-title":"Analysis of the efficacy and safety of immunotherapy in advanced thymoma patients","volume":"12","author":"Hao","journal-title":"Cancer Med"},{"key":"R19","unstructured":"FDA Adverse Event Reporting System (FAERS). US Food & Drug Administration. URL: https:\/\/fis.fda.gov\/extensions\/FPD-QDE-FAERS\/FPD-QDE-FAERS.html [Accessed 25-02-2025]"},{"issue":"6","key":"R20","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","article-title":"The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): development and statement","volume":"47","author":"Fusaroli","journal-title":"Drug Saf"},{"issue":"6","key":"R21","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): explanation and elaboration","volume":"47","author":"Fusaroli","journal-title":"Drug Saf"},{"issue":"1","key":"R22","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40780-016-0048-5","article-title":"Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis using the Japanese Adverse Drug Event Report database","volume":"2","author":"Abe","journal-title":"J Pharm Health Care Sci"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1186\/s40780-015-0035-2","article-title":"Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events","volume":"1","author":"Nakamura","journal-title":"J Pharm Health Care Sci"},{"issue":"10","key":"R24","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40264-013-0061-7","article-title":"Illustration of the Weibull shape parameter signal detection tool using electronic healthcare record data","volume":"36","author":"Sauzet","journal-title":"Drug Saf"},{"key":"R25","doi-asserted-by":"crossref","unstructured":"Zhou C Lin A Li M Qi C Zhang J Luo P . MOAHIT: a web tool for visualizing tumor multi-omics data with human anatomy heatmaps. bioRxiv. Preprint posted online on 2023. [doi: 10.1101\/2022.09.07.506938]","DOI":"10.1101\/2022.09.07.506938"},{"issue":"24","key":"R26","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial","volume":"37","author":"Cho","journal-title":"J Clin Oncol"},{"issue":"6","key":"R27","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1097\/JS9.0000000000000368","article-title":"Toxicities associated with immune checkpoint inhibitors: a systematic study","volume":"109","author":"Kong","journal-title":"Int J Surg"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.12.005","article-title":"Immune checkpoint blockers in patients with unresectable or metastatic thymic epithelial tumours: a meta-analysis","volume":"180","author":"Remon","journal-title":"Eur J Cancer"},{"issue":"1","key":"R29","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01772-4","article-title":"Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives","volume":"22","author":"Ao","journal-title":"Mol Cancer"},{"issue":"8","key":"R30","doi-asserted-by":"publisher","first-page":"5093","DOI":"10.21037\/jtd-21-290","article-title":"The efficacy and safety of immunotherapy in thymic epithelial tumors: more effective, more risky: a systematic review","volume":"13","author":"Song","journal-title":"J Thorac Dis"},{"issue":"23","key":"R31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15235574","article-title":"Thymic epithelial tumor and immune system: the role of immunotherapy","volume":"15","author":"Perrino","journal-title":"Cancers (Basel)"},{"issue":"2","key":"R32","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41577-023-00911-8","article-title":"A guide to thymic selection of T cells","volume":"24","author":"Ashby","journal-title":"Nat Rev Immunol"},{"issue":"9 Suppl 2","key":"R33","doi-asserted-by":"publisher","first-page":"S137","DOI":"10.1097\/JTO.0000000000000299","article-title":"Alterations of the immune system in thymic malignancies","volume":"9","author":"Weksler","journal-title":"J Thorac Oncol"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1288045","article-title":"Autoimmunity in thymic epithelial tumors: a not yet clarified pathologic paradigm associated with several unmet clinical needs","volume":"15","author":"Perrino","journal-title":"Front Immunol"},{"issue":"1","key":"R35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33170-7","article-title":"The immune landscape of human thymic epithelial tumors","volume":"13","author":"Xin","journal-title":"Nat Commun"},{"issue":"8","key":"R36","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1002\/cncr.34678","article-title":"Understanding the landscape of immunotherapy in thymic epithelial tumors","volume":"129","author":"Maniar","journal-title":"Cancer"},{"issue":"3","key":"R37","doi-asserted-by":"publisher","first-page":"124","DOI":"10.5415\/apallergy.0000000000000146","article-title":"From tumor to tolerance: a comprehensive review of immune checkpoint inhibitors and immune-related adverse events","volume":"14","author":"Sutanto","journal-title":"Asia Pac Allergy"},{"issue":"1","key":"R38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27631-8","article-title":"Systematic analysis of drug-associated myocarditis reported in the World Health Organization pharmacovigilance database","volume":"13","author":"Nguyen","journal-title":"Nat Commun"},{"issue":"5","key":"R39","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.acvd.2022.03.003","article-title":"Association of early electrical changes with cardiovascular outcomes in immune checkpoint inhibitor myocarditis","volume":"115","author":"Power","journal-title":"Arch Cardiovasc Dis"},{"issue":"12","key":"R40","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","journal-title":"JAMA Oncol"},{"issue":"18","key":"R41","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","journal-title":"N Engl J Med"},{"issue":"12","key":"R42","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","journal-title":"Lancet Oncol"},{"issue":"12","key":"R43","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1038\/s41591-023-02591-2","article-title":"Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis","volume":"29","author":"Fenioux","journal-title":"Nat Med"},{"issue":"4","key":"R44","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004699","article-title":"Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept","volume":"10","author":"Nguyen","journal-title":"J Immunother Cancer"},{"issue":"7937","key":"R45","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41586-022-05432-3","article-title":"T cells specific for \u03b1-myosin drive immunotherapy-related myocarditis","volume":"611","author":"Axelrod","journal-title":"Nature New Biol"},{"issue":"8041","key":"R46","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41586-024-08105-5","article-title":"Immune responses in checkpoint myocarditis across heart, blood and tumour","volume":"636","author":"Blum","journal-title":"Nature New Biol"},{"issue":"7","key":"R47","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"10","author":"Sakaeda","journal-title":"Int J Med Sci"}],"container-title":["JMIR Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cancer.jmir.org\/2026\/1\/e76908","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T18:08:50Z","timestamp":1782842930000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancer.jmir.org\/2026\/1\/e76908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":47,"URL":"https:\/\/doi.org\/10.2196\/76908","relation":{},"ISSN":["2369-1999"],"issn-type":[{"value":"2369-1999","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"article-number":"v12i2e76908"}}